No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
PharmaEngine, Inc. is a biopharmaceutical firm specializing in the creation and advancement of oncology therapeutics, primarily targeting markets in Taiwan and Europe. Its leading drug candidate is ONIVYDE, an innovative liposomal formulation of irinotecan. This topoisomerase 1 inhibitor is designed to treat metastatic pancreatic cancer. The company's pipeline also includes PEP06, currently in Phase I clinical trials for various cancers, and PEP07. PEP07, a Chk1 inhibitor in preclinical development, is being investigated for its ability to induce DNA damage and programmed cell death (apoptosis), leading to "replication catastrophe" in cancer cells. Established in 2002, PharmaEngine, Inc. maintains its corporate headquarters in Taipei, Taiwan.
www.pharmaengine.comNo one on the platform currently holds 4162.TWO.
No tracked institution reports a position in 4162.TWO as of their last filing.
No one on the platform has traded 4162.TWO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.6% | 16.3% | 16.1% | — | — | — |
| Rev. Growth % | -63.9% | -2.9% | ||||
| Profit Margin % | 42.5% | 52.3% | 48.2% | |||
| Free Cash Flow Margin % | 189.4% | 82.6% | 71.5% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $1.0B | +14.3% | $3.34 | $3.34–$3.34 | — | 1 |
| 2027 | $2.9B | +182.8% | $13.93 | $13.93–$13.93 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 5 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.00 | $0.93 | -6.6% |
| 2026-05-13 | $0.56 | $0.96 | +71.4% |
| 2026-03-03 | $0.79 | $0.91 | +15.2% |
| 2025-10-30 | $0.68 | $0.95 | +39.7% |
| 2025-07-29 | $0.68 | $0.12 | -82.4% |
| 2025-04-29 | $0.57 | $0.71 | +24.6% |
| 2025-02-25 | $5.93 | $9.87 | +66.4% |
| 2024-10-31 | $0.67 | $0.64 | -4.5% |
| -0.66% |
| $4.6B |
| — |
| 4736.TWOTaiDoc Technology Corporation | $129.50 | -1.15% | $12.4B | — |
| 4771.TWVizionfocus Inc. | $206.00 | -2.14% | $12.1B | — |
Source: Financial Modeling Prep · peers by sector/industry